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Abstract
The Salmonella type III secretion system (T3SS) efficiently translocates heterologous proteins into the cytosol of eukaryotic
cells. This leads to an antigen-specific CD8 T-cell induction in mice orally immunized with recombinant Salmonella. Recently,
we have used Salmonella’s T3SS as a prophylactic and therapeutic intervention against a murine fibrosarcoma. In this study,
we constructed a recombinant Salmonella strain translocating the immunogenic H-2Db-specific CD8 T-cell epitope
VILTNPISM (KDR2) from the murine vascular endothelial growth factor receptor 2 (VEGFR2). VEGFR2 is a member of the
tyrosine protein kinase family and is upregulated on proliferating endothelial cells of the tumor vasculature. After single
orogastric vaccination, we detected significant numbers of KDR2-tetramer-positive CD8 T cells in the spleens of immunized
mice. The efficacy of these cytotoxic T cells was evaluated in a prophylactic setting to protect mice from challenges with
B16F10 melanoma cells in a flank tumor model, and to reduce dissemination of spontaneous pulmonary melanoma
metastases. Vaccinated mice revealed a reduction of angiogenesis by 62% in the solid tumor and consequently a significant
decrease of tumor growth as compared to non-immunized mice. Moreover, in the lung metastasis model, immunization
with recombinant Salmonella resulted in a reduction of the metastatic melanoma burden by approximately 60%.
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Introduction
Attenuated recombinant Salmonella enterica serovar Typhimur-
ium has emerged as a promising delivery system for foreign
vaccine antigens [1,2]. Upon close contact with the eukaryotic cell,
a type III secretion system (T3SS) encoded by the ‘‘Salmonella
pathogenicity island 1’’ mediates Salmonella invasion of the host
cell, where the bacterium resides within Salmonella-containing
vacuoles. The T3SS is designed to translocate Salmonella type III
effector proteins directly into the cytosol of target cells [3]. Our
laboratory has focused its research on the genetic manipulation of
attenuated Salmonella strains to endow them with the ability for
efficient induction of MHC class I-restricted immune responses
[4]. We have developed a new vaccination strategy by using the
Salmonella-T3SS to translocate microbial antigens directly into the
cytosol of antigen-presenting cells. The immunodominant p60
antigen from Listeria monocytogenes was fused to the defined N-
terminal translocation domain of the type III effector molecule
Yersinia outer protein E (YopE) [5]. Translocation and cytosolic
delivery of the chimeric YopE/p60 protein into macrophages led
to efficient MHC class I-restricted antigen presentation of the p60
nonamer peptide p60217–225. As determined by enzyme-linked
immunospot assay, mice orally vaccinated with a single dose of
attenuated Salmonella expressing translocated YopE/p60 protein
revealed high numbers of interferon-gamma (IFN-c)-producing
CD8 T cells reactive with p60217–225. In more recent studies, we
demonstrated that the use of Salmonella’s T3SS to induce antigen-
specific cytotoxic T cells is also an attractive strategy to develop
vaccines for the immunoprophylaxis of tumors [6] and is also
suitable as a therapeutic intervention against cancer [7]. For these
experiments, we have established an experimental tumor model in
BALB/c mice [6,7]. The murine fibrosarcoma cell line WEHI 164
[8] was stably transfected with DNA encoding the immunodomi-
nant listerial MHC class I-restricted nonamer epitope p60217–225
[6]. In naı¨ve mice, subcutaneous inoculation of these WEHI-p60
tumor cells resulted in progressive growth of a solid fibrosarcoma
for approximately 14 days without inducing a measurable
frequency of p60217–225-tetramer-positive CD8 T cells [6].
BALB/c mice received a single orogastric immunization with
Salmonella that translocates YopE/p60 via its T3SS [6]. Four weeks
later, mice were challenged subcutaneously with WEHI-p60
tumor cells. In vivo protection studies revealed that 80% of these
mice remained tumor-free, whereas all animals of the non-
vaccinated control group developed tumor growth. Furthermore,
the potential of this vaccination strategy was evaluated with regard
to a therapeutic intervention against cancer [7]. Therefore, we
used the above described model and applied the YopE/p60
expressing Salmonella vaccine strain either simultaneously or 4 days
after subcutaneous tumor injection. Interestingly, 71–80% of the
intravenously and 50–52% of the orogastrically immunized mice
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34214
showed a complete tumor regression after 14 days. In addition, the
distribution of tetramer-positive p60217–225-specific CD8 T cell
subpopulations in blood and tumor tissue was analyzed [7]. Co-
staining with CD62L and CD127 revealed that the frequencies of
p60217–225-specific effector and effector memory CD8 T cells in
blood and in fibrosarcoma tissue were related to the kinetics of
tumor regression.
Tumors have evolved multiple mechanisms to evade the
immune response, including antigen loss, down regulation of the
MHC, and the production of immuno-suppressive factors [9,10].
In addition, many tumors lack expression of co-stimulatory
molecules critical for the activation of naı¨ve T cells. Finally,
tolerance mechanisms are operative in vivo to prevent T cell
activation in response to tumor antigens that are expressed in
many cases also in normal tissue. A new approach to circumvent
some of these problems, is the idea to suppress tumor angiogenesis
by using various types of anti-angiogenic agents [11]. Angiogenesis
is a critical mechanism for tumor progression [12]. The vascular
endothelial growth factor (VEGF) family of proteins is one of the
most potent and specific positive regulators of angiogenesis. These
proteins bind to three tyrosine kinase receptors, vascular
endothelial growth factor receptor 1 (VEGFR1/Flt-1), VEGFR2
(KDR/fetal liver kinase 1, Flk-1), and VEGFR3 (Flt-4) [13].
VEGFR2 is the major mediator of mitogenic, angiogenic, and
permeability-enhancing effects of VEGF in endothelial cells [14].
VEGFR2-null mice die in utero between days 8.5 and 9.5 with no
signs of vasculogenesis or organized blood vessels [15]. Thus,
VEGFR2 plays a crucial role in the processes of vascularization
and angiogenesis. Recent studies in mice have shown that tumor
angiogenesis can also be inhibited when cellular immune responses
are induced against vascular endothelial growth factor receptor 2
(VEGFR2) [16,17].
In this study, we present a novel vaccination strategy to induce
VEGFR2-specific CD8 T cells in mice orally vaccinated with
attenuated recombinant Salmonella enterica serovar Typhimurium.
Induction of cytotoxic T cells targeting VEGFR2-positive
endothelial cells of the tumor vasculature was achieved by
cytosolic delivery of the H-2Db-specific CD8 T-cell epitope
VILTNPISM ( = KDR2) from the murine VEGFR2 using
Salmonella’s T3SS [18]. The efficacy of the Salmonella T3SS-based
vaccination against VEGFR2 was evaluated in a prophylactic
setting in mice that received B16F10 melanoma cells in their right
flank. In additional experiments, the same immunization strategy
was used to reduce dissemination of melanoma pulmonary
metastases. In both tumor models, we could show that vaccination
against VEGFR2 reduced angiogenesis and tumor growth
significantly, highlighting the potential of this novel vaccination
protocol for cancer immunotherapy.
Materials and Methods
Ethics Statement
Animal experiments were approved by the German authorities
(Regierung von Oberbayern, Bavaria, Germany; approval IDs
55.2-1-54-2531.8-08-06 and 55.2-1-54-2531-125-05) and per-
formed according to the legal requirements.
Plasmids, bacterial strains, and growth conditions
The construction of plasmid pHR241 has been outlined in
detail [5]. This low-copy-number expression vector bears the
genetic information for the translocated chimeric YopE1–138/
p60130–477/M45 fusion protein under expression control of the lac
promoter which is constitutively active in Salmonella. M45 is
derived from the E4-6/7 protein of adenovirus and its use for
chimeric protein tagging has been described [5]. Plasmid pHR584
is a derivative of pHR241 and encodes for a hybrid YopE1–138/
VEGFR2352–411 protein. This plasmid was generated by using
standard PCR cloning procedures. Template DNA for VEGFR2/
Flk-1 was kindly provided by Andreas Niethammer (University of
Heidelberg, Germany) [17]. Plasmid pHR584 was transformed
into Salmonella enterica serovar Typhimurium strain SB824 by
electroporation. Strain SB824 was engineered by introducing the
sptP::kan mutant allele from strain SB237 into the DaroA strain
SL3261 by P22HTint transduction [4,19,20]. Serovar Typhimur-
ium was grown in Luria-Bertani medium supplemented with
0.3 M NaCl, pH 7.4, to allow expression of components and
targets of the T3SS encoded by the Salmonella pathogenicity island
1 which mediates Salmonella invasion of host cells [21].
Detection of secreted hybrid YopE protein by Western
Blot analysis
Secreted proteins from Salmonella culture supernatants were
prepared as follows. Briefly, bacterial supernatants were passed
through a 0.45 mm pore-size syringe filter to remove bacteria.
Protein in the bacteria-free medium was precipitated by the
addition of cold trichloroacetic acid to 10% (v/v) and incubated for
2 h on ice. The protein was collected by centrifugation at 4uC,
10,0006 g for 20 min. Pellets were washed in 0.8 ml cold acetone,
dried, and resuspended in phosphate-buffered saline (PBS) buffered
with 80 mM Tris-HCl, pH 8. Samples corresponding to 500 ml
culture supernatant were separated in a 10% discontinuous sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE),
and transferred to nitrocellulose membranes. Hybrid proteins were
detected by immunoblot analysis. Western blots were treated with a
polyclonal antibody against YopE followed by incubation with a
horseradish peroxidase-labeled anti-mouse antibody. Blots were
developed by using a chemiluminescence kit.
Orogastric immunization of mice with recombinant
Salmonella
Specific-pathogen-free female C57Bl/6 mice, 6–8 weeks old,
were purchased from Harlan-Winkelmann (Horst, Netherlands).
For the experiments, animals were housed in groups of five mice
under standard barrier conditions in individually ventilated cages
(Tecniplast, Buguggiate, Italy). Mice were pre-treated orally with
20 mg Streptomycin 24 h prior to Salmonella infections to reduce
the bacterial gut flora and to enhance uptake of the vaccine strain
[22]. Water and food were withdrawn for 4 h before groups of
mice were orally immunized with 56108 colony-forming units
(CFU) of the indicated Salmonella vaccine strain by using round
bottom gavage needles. Thereafter, drinking water ad libidum was
offered immediately and food 2 h post immunization. Animal
experiments were approved by the German authorities and
performed according to the legal requirements.
Analysis of Salmonella loads in small intestine, Peyer’s
patches, mesenteric lymph nodes, livers and spleens
At the indicated time points post immunization, mice were
euthanized by CO2 asphyxiation, and samples from the small
intestine (SI), Peyer’s patches (PP), mesenteric lymph nodes (MLN),
livers and spleens were removed for analysis. Organs were weighed
before resuspending them in 500 ml of 4uC phosphate-buffered
saline, pH 7.4. Then, organs were homogenized in 4uC phosphate-
buffered saline, pH 7.4, either manually or using metal beads in an
automatic homogenizer (Retsch, Wuppertal, Germany). The
numbers of CFU per 1 g were determined by plating appropriate
dilutions on Luria-Bertani agar plates containing ampicillin at
Tumor Vaccination against VEGFR2
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100 mg/ml. It is noteworthy that pHR584 was remarkably stable in
vivo, with 98% of the bacterial population retaining the plasmid 14
days after infection (data not shown).
Generation and purification of H2-Kd tetramers
The generation of tetrameric H2-Kd/KDR2400–408 complexes
has been outlined in detail [23]. Briefly, recombinant H2-Kd
heavy chain and b2-microglobulin were expressed as insoluble
inclusion bodies in Escherichia coli and were further purified. The
H2-Kd heavy chain molecule was mutated to remove the
transmembrane and cytosolic domain and to add a specific
biotinylation site at the C-terminus. Purified proteins were
refolded in vitro in the presence of high concentrations of synthetic
peptides (Biosythan, Berlin, Germany) to form stable and soluble
MHC/peptide complexes. Complexes were specifically biotiny-
lated in vitro by adding the enzyme BirA, d-biotin, and ATP. After
further purification, biotinylated MHC/peptide complexes were
multimerized with streptavidin-PE (SA-PE; Molecular Probes,
Eugene, OR). Tetrameric complexes were purified by gel filtration
and stored at 2–5 mg/ml at 4uC in phosphate-buffered saline
(pH 8.0) containing 0.02% sodium azide, 1 mg/ml pepstatin,
1 mg/ml leupeptin, and 0.5 ml EDTA.
Preparation of cells from spleens
At the indicated time points, spleens were removed from animals,
harvested by dissociation through a wire mesh, and subsequently
resuspended in RP10+, which consists of RPMI 1640 (Invitrogen,
Karlsruhe, Germany) supplemented with 10% fetal calf serum, l-
glutamine, HEPES (pH 7.5), 2-mercaptoethanol, penicillin
(100 U/ml), streptomycin (100 mg/ml), and gentamicin (50 mg/ml).
MHC tetramer staining and FACS analysis
The KDR2400–408-specific T cell populations were detected
with phycoerythrin (PE)-conjugated, tetrameric MHC I/peptide
complexes and concurrently stained for other surface molecules
using directly conjugated monoclonal antibodies as described
previously [23,24]. Briefly, cells were incubated with ethidium
bromide monoazide for live/dead discrimination in FACS-
staining buffer (phosphate-buffered saline pH 7.45, 0.5% bovine
serum albumin, and 0.02% sodium azide). Subsequently, cells
were stained with the above mentioned MHC class I tetramer and
surface markers for 1 h. The following monoclonal antibodies
were used: anti-CD8a (clone 53-6.7, BD, Heidelberg, Germany),
anti-CD62L (clone Mel-14, NatuTec, Frankfurt, Germany), and
anti-CD127 (clone A7R34, NatuTec). Cells were resuspended in
staining buffer and fixed in 1% paraformaldehyde/phosphate-
buffered saline (pH 7.45). Data were acquired on a FACSCanto II
(BD Biosciences, San Jose, CA) and further analyzed with FlowJo
software (TreeStar, Ashland, OR). C57Bl/6 mice were orogas-
trically immunized with a single dose of 56108 SB824 (pHR584).
Data are displayed as relative numbers of H2-Kd/KDR2400–408-
tetramer-positive CD8 T cells that were normalized on the
background tetramer staining in spleens of non-immunized mice.
Flank tumor model
Subconfluent B16F10 cells [25] that were purchased from
ATCC (Manassas, VA, USA) were trypsinized, washed, and
resuspended in RPMI-1640 (Invitrogen, Karlsruhe, Germany).
The cell suspension (36105 cells in 100 ml) was injected
subcutaneously into the right flank of C57BL/6 mice. Groups of
five mice were used and randomly divided. Tumor growth was
monitored by measuring the length and width of the individual
tumors using a calliper [6,7]. At the end of the experiment, mice
were euthanized by CO2 asphyxiation and tumors were removed
for immunohistological analysis.
Artificial metastasis model
Subconfluent B16F10 cells [25] were trypsinized, washed, and
resuspended in RPMI-1640. The cell suspension (26105 cells in
100 ml) was injected intravenously into the tail vein of C57BL/6
mice in order to mimic the metastatic process. Mice were observed
for symptoms of illness and two weeks after the injection
euthanized by CO2 asphyxiation and lungs were removed and
analyzed for metastases. Using Photoshop software, the number of
metastases and the metastases-covered lung area were calculated.
Histology and immunohistochemistry
Melanoma tumors were prepared for cryosection and 7 to
10 mm cryosections were stained with a FITC-conjugated CD31
(PECAM-1, Becton Dickinson, Heidelberg, Germany) antibody
and DAPI. Additionally, HE staining was performed on cryosec-
tions. Stained cryosections were analyzed using the Olympus
BX61 immunofluorescence microscope. The phase analysis and
particle detection program of Cell‘P software from Olympus were
used for measuring the fluorescence intensity and the area of the
CD31-FITC staining, respectively.
Statistical analysis
The statistical significance of the results was checked with the
non-parametric Mann-Whitney-U-Test at the 0.005 significance
level, or as indicated. All tests were performed using the SigmaStat
software (Systat Software GmbH, Erkrath, Germany).
Results
Construction of chimeric YopE1–138/VEGFR2352–411 and
analysis of its secretion efficacy by Western Blotting
To obtain a Salmonella vaccine strain for anti-angiogenic
immunotherapy, a protein fragment containing the immunodomi-
nant KDR2 (VILTNPISM) epitope of the murine VEGFR2 was
fused to YopE. YopE is a type III effector protein of Yersinia
enterocolitica and acts as a carrier molecule to translocate the
translational fusion protein into the cytosol of antigen-presenting
cells (e.g. macrophages and dendritic cells) [5]. The N-terminal 138
amino acids of YopE containing the secretion and translocation
domains [26,27] were fused to amino acids 352 to 411 of Flk-1 [17].
Thus, the newly constructed low-copy-number plasmid pHR584
bears the genetic information for chimeric YopE1–138/VEGFR2352–
411 including the nonamer epitope KDR2 (VEGFR2400–408) (Fig. 1a).
The bacterial whole cell lysate in Fig. 1b reveals that the constitutive
expression of the respective gene fusion by the lac promotor led to the
stable production of the hybrid protein by Salmonella. Furthermore it
is shown that chimeric YopE1–138/VEGFR2352–411 is efficiently
secreted into the Salmonella cultural supernatant. Previously, we have
demonstrated that secretion of YopE1–138/p60 correlates with
T3SS-dependent translocation of this hybrid protein into the cytosol
of macrophages by serovar Typhimurium [5]. As demonstrated in
Fig. 1b, both YopE1–138/p60130–477 and YopE1–138/VEGFR2352–
411 are produced and secreted in comparable amounts by Salmonella.
As expected, in the supernatant of plasmid-less SB824 (negative
control) no protein fragment was detected.
Time course of colonization and persistence of
Salmonella SB824 (pHR584) in mouse tissues
In a recently published study, we orally immunized BALB/C
mice with the attenuated serovar Typhimurium aroA/sptP mutant
Tumor Vaccination against VEGFR2
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strain SB824 (pHR241) expressing translocated YopE1–138/
p60130–477, and the kinetics of colonization and persistence of
the bacteria in vivo were investigated [28]. In the current study,
C57Bl/6 mice were orogastrically vaccinated with 56108 SB824
(pHR584) or SB824 and the time course of colonization was
determined by counting the numbers of viable bacteria, as CFU
per g tissue, in the small intestine (SI), in Peyer’s Patches (PP), in
mesenteric lymph nodes (MLN), in the liver and the spleen on days
2, 6, 14, 21, and 31 after immunization. No significant differences
between the colonization kinetics of both Salmonella strains were
detected. As shown in Fig. 2, SB824 (pHR584) and SB824 were
already recovered from all mouse tissues two days after orogastric
application. From day 2 to day 6 the amount of Salmonella in all
organs decreased significantly. On day 14, both strains could not
be isolated from the liver anymore, whereas in all other tissues
salmonellae were still detected. On days 21 and 31, SB824
(pHR584) and SB824 were still present in MLN albeit in very few
numbers. Taken together, the newly constructed vaccine strain
rapidly colonized intestinal mouse tissues after orogastric immu-
nization and persisted for at least 14 days.
KDR2-specific CD8 T-cell response after single orogastric
immunizations
The potential of attenuated serovar Typhimurium expressing
chimeric YopE1–138/VEGFR2352–411 to induce KDR2-specific
CD8 T cells in vivo was investigated. For this purpose, C57Bl/6
mice were orogastrically immunized with a single dose of 56108
SB824 (pHR584). Control mice remained non-immunized. After
6, 14, 21, and 31 days, spleens of vaccinated mice were removed
and the relative numbers of H2-Kd/KDR2400–408-tetramer-
positive CD8 T cells were assessed. In Fig. 3a (white bars) it is
demonstrated that the highest level of KDR2-specific CD8 T cells
(0.102%60.01) was detected as early as 6 days after immunization
followed by a gradual decline of antigen-specific T cell frequencies
on days 14 and 21. On day 31, no significant numbers of KDR2-
specific CD8 T cells were detected like in non-vaccinated mice
(black bars). In summary, orogastric immunization with SB824
(pHR584) can be used to induce a rapid KDR2-specific CD8 T
cell response within 6 days after prime vaccination.
Co-staining of KDR2400–408-specific CD8 T cells with
CD62L and CD127 to determine differentiation patterns
into phenotypically distinct CD8 T cell subsets
Tetrameric H2-Kd/KDR2400–408 complexes were used to
characterize the development of KDR2-specific effector (TEC),
effector memory (TEMC) and central memory (TCMC) CD8 T cells
in spleens of immunized mice by co-staining with CD62L and
CD127. TCMC reside preferentially in lymphoid organs and lack
immediate effector functions [29], whereas TEMC migrate mainly
Figure 1. Construction of chimeric protein YopE1–138/VEGFR2352–411 and its secretion efficacy. A Schematic representation of the
translational fusion of YopE1–138 and VEGFR2352–411 encoded by plasmid pHR584. B Western blot analysis of hybrid protein YopE1–138/VEGFR2352–411
showing its stable production and efficient secretion into the Salmonella culture supernatant. SB824 (pHR241) expressing YopE1–138-p60 served as a
positive and plasmid-less SB824 as a negative control.
doi:10.1371/journal.pone.0034214.g001
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into non-lymphoid tissue and elicit immediate effector functions on
antigen reencounter. Recent results indicate that interleukin-7
receptor a-chain (CD127) surface expression is a marker for long-
living memory T cells [30]. The combination of surface staining
for CD127 and L-selectin (CD62L) further separates between
TCMC (CD127
high/CD62Lhigh) and TEMC (CD127
high/CD62Llow)
allowing to distinguishing TEC (CD127
low/CD62Llow) from
memory T cells at early time points of in vivo immune responses.
In our study, C57Bl/6 mice were orogastrically immunized with
a single dose of 56108 SB824 (pHR584). Spleens from vaccinated
mice revealed TEC as the predominant KDR2-specific CD8 T-cell
subset (6069.99%) 6 days after vaccination, whereas memory T
cells (TEMC and TCMC) represented only 1563.72% and 12612%
of these specific CD8 T cells, respectively (Fig. 3b). However,
analysis of the KDR2-specific CD8 T cell subpopulations on day
14 showed 45616.85% TCMC and 25613.27% TEMC. Thus, the
subset of TEC was significantly reduced to 22618.67%. Three
weeks after orogastric immunization, .70% of KDR2-specific
CD8 T cells were CD127-positive and thus revealed a memory T
cell phenotype (TCMC 40614.86% and TEMC 32%618.12%,
respectively). Taken together, the analysis of the kinetics of KDR2-
specific CD8 T cell subpopulation formation revealed a clear trend
towards the induction of memory T cell subsets.
Vaccination with Salmonella SB824 (pHR584) leads to
reduced angiogenesis in the melanoma flank tumor
model
Previously, Niethammer et al. have shown that DNA vaccination
against VEGFR2 resulted in a CD8 T cell-dependent reduction of
tumor angiogenesis and tumor growth [17]. In a next set of
experiments, we addressed the question whether vaccination of
C57Bl/6 mice with the attenuated Salmonella strain SB824
(pHR584) and the subsequent induction of KDR2400–408-specific
CD8 T cells reduces the formation of new blood vessels in the
melanoma flank tumor model. As above, C57Bl/6 mice were
orogastrically immunized with a single dose of 56108 SB824
(pHR584). Control mice received plasmid-less SB824 or remained
non-immunized. On day 30, 36105 B16F10 melanoma cells were
applied subcutaneously into the flank of mice and tumor growth
was monitored for two weeks. At the end of the experiment, on
day 44, tumors from mice of all three groups were prepared for
histological analysis. Haematoxylin and eosin (HE) staining
revealed the typical structure of melanoma tumor tissue (Fig. 4a,
i–iii). Endothelial cells are an essential part of blood vessels and
express CD31 (platelet/endothelial cell adhesion molecule,
PECAM-1) [31]. Thus, CD31 staining reveals the amount of
blood vessels in tumor sections. We performed immunofluores-
cence microscopy of tumor cryosections stained with a FITC-
conjugated CD31 antibody and DAPI to visualize cell nuclei
(Fig. 4a, iv–vi). At a first glance, tumor sections of mice vaccinated
with SB824 (pHR584) revealed reduced green fluorescent areas
(Fig. 4a, vi) in comparison to tumor sections of control mice
(Fig. 4a, iv and v) suggesting a reduced angiogenesis in the
melanoma tissue. Images shown in Fig. 4a are representative for
approximately 50 tumor cryosections from different mice of each
experimental group. The impression of decreased angiogenesis in
tumors of mice immunized with SB824 (pHR584) could be
verified by measuring the fluorescence intensity and the area of the
CD31-FITC staining with the phase analysis and particle
detection program of Cell‘P software from Olympus. The mean
area of the CD31-FITC fluorescence in tumors of non-immunized
mice was defined as 100%. Tumors of mice immunized with
plasmid-less SB824 revealed exactly the same fluorescence area
(Fig. 4b). However, this area was strikingly decreased to 38% in
tumors of mice that were vaccinated with SB824 (pHR584).
Vaccination with SB824 (pHR584) leads to reduced
melanoma growth in the flank tumor model
To investigate the effect of Salmonella-mediated tumor vaccina-
tion against VEGFR2, we monitored melanoma growth in the
above described subcutaneous tumor model. Again, C57Bl/6 mice
were orogastrically immunized with a single dose of 56108 SB824
(pHR584). Control mice received plasmid-less SB824 or remained
non-immunized. On day 30, 36105 B16F10 melanoma cells were
applied subcutaneously into the flank of mice and tumor growth
was determined on days 36, 38, 40, 42, and 44. Representative
Figure 2. Colonization kinetics in different organs after oral vaccination with Salmonella SB824 (pHR584) or SB824. Small intestines
(SI), Peyer’s Patches (PP), mesenteric lymph nodes (MLN), spleens and livers of five mice were analyzed for the amount of Salmonella (determined as
colony-forming units per gram tissue; CFU/g) on days 2, 6, 14, 21 and 31 post immunization. Each experiment was performed at least twice with
similar results.
doi:10.1371/journal.pone.0034214.g002
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pictures of the clinical outcome of tumor development on days 38
and 42 are shown in Fig. 5a. Obviously, vaccination with SB824
(pHR584) significantly reduced melanoma tumor growth in
C57Bl/6 mice. In fact, at every time point of tumor measurement,
the mean melanoma areas in mice immunized with SB824
(pHR584) were significantly smaller (approximately 50%) than in
mice of both control groups (Fig. 5b). For example, on day 44, the
tumor area in mice vaccinated with SB824 (pHR584) was 62 mm2
(623 mm2), whereas in both control groups the melanoma areas
were 120 mm2 (647 mm2). Interestingly, 1 out of 10 mice
immunized with SB824 (pHR584) remained tumor-free until day
44, while all 20 mice of the both control groups developed tumor
growth. Taken together, these data suggest that vaccination of
mice with SB824 (pHR584) significantly reduces growth of
subcutaneously applied melanoma tumor cells.
Vaccination with Salmonella SB824 (pHR584) reduces
dissemination of melanoma pulmonary metastases
Tumor vaccination using Salmonella SB824 (pHR584) was also
tested in a B16 melanoma metastasis model. Therefore, C57Bl/6
mice were orogastrically vaccinated with SB824 (pHR584)
followed by a tumor challenge with an intravenous injection of
B16 melanoma cells on day 30. Mice of the control group
remained non-immunized. Two weeks after the challenge (day 44),
lungs were prepared from sacrificed mice and analyzed for
metastatic growth. Fig. 6a and b show macroscopic views of the
lungs and magnified single lobes from ten mice of both
experimental groups. Remarkable differences in the appearance
of the lungs were obvious. Lungs of non-immunized mice seemed
to be almost totally covered with melanoma metastases, whereas
lungs of vaccinated mice revealed only single metastatic spots on
Figure 3. KDR2-specific CD8 T-cell response and kinetics of KDR2400–408-specific CD8 T cell subpopulations. A MHC tetramer staining
using tetrameric H2-Kd/KDR2400–408 complexes and flow cytometric analysis of murine spleen cells were performed on days 6, 14, 21 and 31 after
single orogastric immunization with Salmonella SB824 (pHR584). Relative numbers of H2-Kd/KDR2400–408-tetramer-positive CD8 T cells are shown for
five mice vaccinated with SB824 (pHR584) (black bars) and for five non-immunized mice (grey bars, control). Asterisks indicate values that differ
significantly from the corresponding values obtained from mice of the control group (*, p#0.005). B Differentiation patterns of KDR2400–408-specific
CD8 T cells into phenotypically distinct subsets on days 6, 14, and 21 after single orogastric vaccination with Salmonella SB824 (pHR584) are displayed
as % of KDR2400–408-specific CD8 T cells. KDR2400–408-specific CD8 T cells were stained for expression of CD127 and CD62L and analyzed by flow
cytometry. CD127high/CD62Lhigh central memory CD8 T cells, TCMC, white bars; CD127
high/CD62Llow effector memory CD8 T cells, TEMC, grey bars;
CD127low/CD62Llow effector CD8 T cells, TEC, black bars. Each experiment was performed at least twice with similar results.
doi:10.1371/journal.pone.0034214.g003
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their surfaces. Using Photoshop software, the amount of
metastases and the surface area of the lungs covered with
metastases could be determined (Fig. 6c and d). In lungs of mice
immunized with SB824 (pHR584), the average metastatic burden
(48 spots) was reduced by approximately 60% as compared to non-
immunized mice (118 spots) (Fig. 6c). About 35% of the lung
surface areas from mice of the former group were covered with
metastases, whereas the lungs from mice of the latter group
revealed almost 90% coverage with metastases (Fig. 6d). Interest-
ingly, the health condition of mice vaccinated with SB824
(pHR584) appeared to be unaltered. In contrast, non-immunized
mice showed signs of sickness like anorexia and malnutrition
during the time of metastatic dissemination. Mice vaccinated with
plasmid-less SB824 revealed a comparable metastatic burden and
similar signs of sickness as non-immunized mice (data not shown).
Thus, a Salmonella-mediated unspecific ‘‘bystander-effect’’ respon-
sible for reduced dissemination of pulmonary metastases is
unlikely.
Discussion
Live attenuated bacteria (e. g. Salmonella enterica, Listeria
monocytogenes and Mycobacteria) have been widely used as vaccine
carriers for foreign antigen display to induce cell-mediated
immunity [1,2]. In the past, the T3SS of Salmonella enterica serovar
Typhimurium became an attractive tool for heterologous protein
delivery directly into the cytosol of macrophages and dendritic
cells resulting in vigorous antigen-specific CD8 T cell priming and
the induction of protective immunity against viruses, bacteria and
tumors [4–7]. Unquestionable, CD8 T cells play a pivotal role in
the host defence against viruses, intracellular bacteria and tumors.
However, the induction of potent CD8 T cell responses to fight
microbes or cancer remains a major challenge in vaccine
development. Here we show that T3SS-mediated antigen delivery
by Salmonella can be used for vaccination against VEGFR2 to block
tumor angiogenesis.
Tumor angiogenesis is a very attractive target for cancer
therapy for several obvious reasons. In general, angiogenesis is
required for tumor growth implicating that an anti-angiogenic
vaccination approach can be theoretically used to fight a number
of different tumor types [16,17]. Targeting endothelial cells instead
of cancer cells benefits from the genetic stability of benign cells in
contrast to malign tumor cells. Endothelial cells are not associated
with mutations or downregulation of MHC molecules for antigen
presentation [16]. Furthermore, endothelial cells of the tumor
vasculature are readily and better accessible for therapeutics
(effector T cells, antibodies) via the bloodstream than tumor cells
[32]. Eventually, targeting endothelial cells for tumor therapy
Figure 4. Vaccination with Salmonella SB824 (pHR584) leads to reduced angiogenesis in the melanoma flank tumor model. A On day
44 of the experiment, melanoma tumors of five mice were removed, prepared for histological analysis and stained with HE (i–iii). Additionally, tumor
sections were stained with a FITC-conjugated CD31 antibody (green) and DAPI (blue), and analyzed by immunofluorescence microscopy (iv–vi).
Representative images of tumor sections from three experimental groups are displayed. B Quantification of the area of the green FITC-fluorescence
was performed using Cell‘P software (Olympus). The mean areas of CD31-FITC fluorescence from tumor sections of experimental groups SB824 and
SB824 (pHR584) are shown as fraction of the mean area of CD31-FITC fluorescence from tumor sections of the non-immunized control group in %.
Asterisks indicate values that differ significantly from the corresponding values obtained from mice of both control groups (**, p#0.001). Each
experiment was performed at least twice with similar results.
doi:10.1371/journal.pone.0034214.g004
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Figure 5. Significant reduction of melanoma tumor growth by Salmonella-mediated vaccination against VEGFR2. A Photographs of the
clinical outcome of C57Bl/6 mice with subcutaneous B16 melanoma tumors. From left to right representative mice from experimental groups NI,
SB824 and SB824 (pHR584) on day 38 and day 42 are shown. B Tumor growth was monitored over time and the mean tumor area was calculated.
Asterisks indicate values that differ significantly from the corresponding values obtained from mice of both control group (*, p#0.005).
doi:10.1371/journal.pone.0034214.g005
Figure 6. Analysis of lung metastasis after Salmonella-mediated vaccination against VEGFR2. A In the artificial lung metastasis model,
C57Bl/6 mice were orogastrically vaccinated with SB824 (pHR584) followed by a tumor challenge with an intravenous injection of B16 melanoma cells
on day 30 in order to mimic the metastatic process. Lungs of ten mice vaccinated with SB824 (pHR584) and magnification of single lobes are
displayed. B Lungs of ten non-immunized mice and magnification of single lobes. C Average number of metastatic spots on lungs (**, p#0.001) D
Average percentage of surface area of the lungs covered with metastases (**, p#0.001). Each experiment was performed at least twice with similar
results.
doi:10.1371/journal.pone.0034214.g006
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bears a multiplicity effect because each tumor vessel supplies
hundreds of tumor cells [33].
VEGFR2, which is upregulated on proliferating endothelial
cells of the tumor vasculature, plays an essential role in tumor
neoangiogenesis and is therefore an ideal target for anti-angiogenic
therapy approaches [16,17]. The importance of VEGFR2 in
antitumor therapy was demonstrated in several studies using
different strategies. Besides approved drugs like the monoclonal
antibody bevacizumab targeting VEGF-A [34], diverse studies in
preclinical and clinical trials efficiently showed the antitumor effect
of fixed xenogeneic endothelial cells [35], VEGFR2-conjugated
proteins [36], VEGFR2-pulsed dendritic cells [16,32], liposomal
peptides of the fibroblast growth factor-2 [37], several DNA-
vaccines against survivin, integrin b3, VEGFR and VEGFR2 [33]
and viral vectors for DNA-vaccines [38]. Niethammer et al. could
show that DNA-vaccination can block tumor angiogenesis by
induction of a T cellular immune response against VEGFR2 [17].
This DNA-vaccine efficiently protected mice from the growth of
melanoma, colon carcinoma and small lung cell carcinoma cells
and reduced metastasis.
Our novel vaccination strategy to induce VEGFR2-specific
CD8 T cells in mice is based on a recombinant Salmonella strain
that delivers the H-2Db-specific CD8 T-cell epitope VILTNPISM
( = KDR2) from the murine VEGFR2 directly into the cytosol of
antigen-presenting cells via the bacterium’s T3SS. In mice orally
immunized with the Salmonella vaccine strain SB824 (pHR584),
KDR2-specific CD8 T cells aimed to target endothelial cells were
directly monitored by KDR2-MHC class I-tetramer staining. The
latter technique was further used to characterize the development
of KDR2-specific effector, effector memory and central memory
CD8 T cells in murine spleens by co-staining with CD62L and
CD127 [30,39]. Effector and memory T cells display diversity with
respect to their effector functions, homing potential, and
proliferative capacity [40]. TEC dominate the expansion phase,
migrate to peripheral organs, and display immediate effector
function. TEMC preferentially home to peripheral tissues and
respond to antigen encounter with immediate effector function but
poor numeric expansion [41]. In contrast, TCMC home to
lymphoid organs, can vigorously expand upon antigen reencoun-
ter and are therefore potentially assigned to the crucial T cell
population that confers long-lasting protective immunity against
microbial pathogens [42]. However, proliferative capacity does
not necessarily correlate with protection against infection, since
TCMC-like CD8 T cells induced by vaccination with heat-killed L.
monocytogenes reveal vigorous proliferation and expansion after
challenge with live Listeria, but do not protect against listeriosis as
determined by clearance of the bacteria [43]. These findings were
supported by a recent study demonstrating that TEMC are more
effective than TCMC in conferring protection in the murine Listeria
infection model [41,44]. As mentioned above, the analysis of the
kinetics of KDR2-specific CD8 T cell subpopulation formation
after SB824 (pHR584) vaccination revealed a clear trend towards
the induction of both memory T cell subsets. Proliferation of
tumor cells appears less fast as bacterial cell division. It is tempting
to speculate that KDR2-specific TCMC and TEMC constitute an
ideal pair of CD8 T cell subsets to tackle cancer cells. However,
further experiments such as functional ex vivo assays analyzing the
killing activity and cytokine production are needed to characterize
KDR2-specific CD8 T cells and their impact on the observed anti-
tumor effects.
In further experiments, the efficacy of Salmonella T3SS-based
vaccination was evaluated in a prophylactic setting to protect mice
from lethal challenges with B16F10 melanoma cells in a xenograft
flank tumor model, and to reduce dissemination of spontaneous
pulmonary metastases in a B16 melanoma model. As compared to
non-immunized mice, immunofluorescence staining of flank tumor
sections with an antibody against CD31 revealed a reduction of
angiogenesis in the solid melanoma by 62% in mice vaccinated
with SB824 (pHR584). Most likely, this effect was mediated by
KDR2-specific CD8 T cells that specifically recognized and
destroyed VEGFR2-positive endothelial cells of the tumor
vasculature. As a consequence, tumor growth was significantly
reduced in vaccinated mice by approximately 50%. Niethammer
and colleagues have previously demonstrated a comparable anti-
angiogenic effect using a DNA-vaccination strategy against
VEGFR2 [17]. They observed a reduction of angiogenesis by
70% in a colon carcinoma model. Dong et al. used a vaccination
approach with KDR peptides and reported a reduction of
angiogenesis by 70%, too [18]. Similarly to our Salmonella-based
vaccination strategy, this peptide-mediated immunization de-
creased tumor growth by 50%.
In the artificial lung metastasis model, immunization with
SB824 (pHR584) resulted in a reduction of the metastatic
melanoma burden by approximately 60%. An even higher rate
of reduction (,85%) was demonstrated by Li and colleagues using
dendritic cells pulsed with VEGFR2-peptid for vaccination
purposes [16]. In our experimental set-up, about 35% of the lung
surface areas from mice vaccinated with SB824 (pHR584) were
covered with metastases, whereas the lungs from non-immunized
mice showed 90% coverage with metastases. DNA vaccination
against VEGFR2 by Niethammer et al. also counteracted the
process of metastasis. Less than 20% of the surface area of murine
lungs was covered with metastases as compared to more than 50%
in non-vaccinated mice [17]. Thus, interference of specific CD8 T
cells with angiogenesis impedes the efficient formation of
metastases.
Since VEGFR2 is also expressed at lower levels in normal
vascular endothelium, vaccination against this receptor could
theoretically cause side effects or an autoimmune response. In the
DNA vaccination approach of Niethammer et al. the wound
healing was delayed following vaccination but the fertility of mice
was not affected [17]. Controversially, Li et al. did not observe a
delay in wound healing by dendritic cell (DC)-based vaccination
against VEGFR2. However, the authors found an inhibitory effect
of DC-VEGFR2 immunization on fetal development [16]. Finally,
Dong et al. did not detect any obvious side effects following
vaccination with antigenic peptides against VEGFR2 [18]. In our
study, we did not detect any obvious side effects either.
An interesting question arises from the observation that the
vaccine strain SB824 (pHR584) was recovered from the gut,
lymph nodes and even the spleen as early as two days after
orogastric application. What is the site of KDR2-specific CD8 T-
cell priming? Further experiments are needed to determine
whether these antigen-specific T cells are derived from the gut,
and then disseminate to the spleen or to the site of tumor growth,
or, alternatively, are stimulated in lymph nodes.
Interestingly, Nishikawa et al. observed the phenomenon of
epitope spreading using the Salmonella T3SS as an antigen delivery
system [45]. The authors engineered a serovar Typhimurium
strain expressing the human germ cell antigen NY-ESO-1 via the
T3SS. NY-ESO-1 is often expressed by tumor cells but not by
normal somatic cells. Oral administration of serovar Typhimur-
ium NY-ESO-1 to mice led to the regression of established NY-
ESO-1-expressing tumors. However, intratumoral inoculation of
this Salmonella strain into NY-ESO-1-negative tumors resulted in
the delivery of the antigen in vivo and led to tumor regression in the
presence of preexisting NY-ESO-1-specific CD8 T cells. In
addition, specific T-cell responses against at least two unrelated
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tumor antigens not contained in the vaccine strain were observed,
demonstrating epitope spreading. In future experiments we will
investigate whether the phenomenon of epitope spreading also
influences Salmonella T3SS-mediated vaccination against
VEGFR2.
This is the first report demonstrating that Salmonella T3SS-
mediated antigen delivery can be used for efficient VEGFR2-
specific CD8 T cell induction. This novel method of cancer
immunotherapy might complement or even boost other anti-
angiogenesis immunization strategies such as DNA or peptide
vaccination. To confirm the general potential of our Salmonella-
based vaccination strategy to elicit an anti-tumor effect, we plan to
use several tumor lines in future experiments. Interestingly, is has
recently been demonstrated for the first time that a VEGFR2-
expressing subset of T regulatory T cells (Tregs) exists [46]. It is
conceivable that VEGFR2 might become a new therapeutic target
for controlling Tregs with highly suppressive function in tumor
immunotherapy. Furthermore, two recently published studies have
identified blood vessels grown directly from cancer cells suggesting
that tumor cells build-up their own vasculature using a mechanism
related to cancer-stem cells [47,48]. These new findings reinforce
the need for alternative anti-angiogenic vaccination strategies.
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